Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
Clinical trial NCT06141265 · RECRUITING
Trial details
- NCT number
- NCT06141265
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-01
- Primary completion
- 2026-09-01
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.